Collegium Pharmaceutical (COLL) Long-Term Deferred Tax (2021 - 2025)
Collegium Pharmaceutical (COLL) has 5 years of Long-Term Deferred Tax data on record, last reported at $102.5 million in Q3 2025.
- For Q3 2025, Long-Term Deferred Tax rose 41.33% year-over-year to $102.5 million; the TTM value through Sep 2025 reached $102.5 million, up 41.33%, while the annual FY2024 figure was $98.0 million, 273.33% up from the prior year.
- Long-Term Deferred Tax reached $102.5 million in Q3 2025 per COLL's latest filing, up from $92.0 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $102.5 million in Q3 2025 and bottomed at $24.0 million in Q4 2022.
- Average Long-Term Deferred Tax over 5 years is $51.7 million, with a median of $32.4 million recorded in 2024.
- Peak YoY movement for Long-Term Deferred Tax: tumbled 69.31% in 2022, then soared 273.33% in 2024.
- A 5-year view of Long-Term Deferred Tax shows it stood at $78.0 million in 2021, then crashed by 69.31% to $24.0 million in 2022, then grew by 9.64% to $26.3 million in 2023, then skyrocketed by 273.33% to $98.0 million in 2024, then grew by 4.53% to $102.5 million in 2025.
- Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $102.5 million in Q3 2025, $92.0 million in Q2 2025, and $91.7 million in Q1 2025.